Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Philippe Moreau, Shaji K. Kumar, Jesús San Miguel, Faith Davies, Elena Zamagni, Nizar Bahlis, Heinz Ludwig, Joseph Mikhael, Evangelos Terpos, Fredrik Schjesvold, Thomas Martin, Kwee Yong, Brian G.M. Durie, Thierry Facon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels van de Donk, Sagar Lonial, Michele CavoSigurdur Y. Kristinsson, Suzanne Lentzsch, Roman Hajek, Kenneth C. Anderson, Cristina João, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafael Fonseca, Annette Vangsted, Katja Weisel, Rachid Baz, Vania Hungria, Jesus G. Berdeja, Fernando Leal da Costa, Angelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloisa Riva, Peter Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf Henrik Mellqvist, Dominik Dytfeld, Jean Luc Harousseau, Hartmut Goldschmidt, Jacob Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksac, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah Holstein, Orhan Sezer, Simon Harrison, Hareth Nahi, Gordon Cook, Maria Victoria Mateos, S. Vincent Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson

Research output: Contribution to journalReview articlepeer-review

Abstract

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)e105-e118
JournalThe Lancet Oncology
Volume22
Issue number3
DOIs
StatePublished - Mar 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group'. Together they form a unique fingerprint.

Cite this